2024-518636-36-00招募中4 期
Phase Ib/II trial of the combination of atezolizumab with dendritic cell vaccination as maintenance treatment in patients with extensive stage small cell lung cancer (ES-SCLC) after induction treatment.
Instituto Oncologico Dr. Rosell S.L., Instituto Oncologico Dr. Rosell S.L.3 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2024年10月10日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 发起方
- 入组人数
- 20
- 试验地点
- 3
- 主要终点
- Progression-Free Survival (PFS) rate at 6 months: Calculated as the percentage of participants alive and without disease progression, as assessed by the Investigator using RECIST v1.1, at 6 months.
研究概览
简要总结
Progression-free survival (PFS) rate at 6 months.
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- •Histological diagnosis of extensive stage small cell lung cancer (ES-SCLC). Unequivocally confirmed diagnosis of SCLC by histology preferably including the presence of neuroendocrine features by immunohistochemistry.
- •Written informed consent of approved by the investigator’s Institutional Review Board (IRB)/Independent Ethics Committee (IEC), prior to the performance of any trial activities.
- •Male or female subjects aged ≥ 18 years.
- •Measurable disease by RECIST.1.1 criteria.
- •Highly effective contraception for both male and female subjects throughout the study and for at least 30 days after last atezolizumab treatment administration if the risk of conception exists.
- •Negative serum pregnancy test at screening for women of childbearing potential. Female subjects must either be of non-reproductive potential (ie, post-menopausal by history: ≥60 years old and no menses for ≥1 year without an alternative medical cause; OR history of hysterectomy, OR history of bilateral tubal ligation, OR history of bilateral oophorectomy) or must have a negative serum pregnancy test upon study entry.
- •Central negative serologic determination to: HBsAg, Anti-HBc, HBV, HCV, HCV RNA, HIV-I RNA, Agp24 IIIV + AC IIIV 1⁄2 (MLIA) serum, IgG antigen core v. hepatitis B, RPR (Ac reagínicos Lues-RPR, serum), Ac anti HTLV I/II (if patient came from endemic zone), Ac anti Trypanosoma Cruzi, Chagas, (if patient came from endemic zone), when RPR positive or doubtful for confirmation: IgG T. pallidum (ELISA) IgM T. pallidum (ELISA), when IgG T. Pallidum doubtful: Pt confirmatory IgG/IGM, T pallidum (LIA). SARS-CoV-2 RNA.
- •Centrally confirmed tumor tissue viability for ADC immunotherapy preparation.
- •No previous cancer treatment for advanced disease
- •Life expectancy at least 16 weeks
- •ECOG performance status 0 or
- •Adequate normal organ and marrow function as defined below: 6.a Absolute neutrophil count ≥ 1.5 x 10 9 cells/L 6.b Platelets ≥ 100 x 10 9 /L 6.c Hemoglobin ≥ 9 g/dL 6.d Aspartate and alanine aminotransferases (AST, ALT) ≤ 2.5 x upper limit of normal (ULN) (≤ 5 x ULN, if documented liver metastases are present) 6.e Total bilirubin ≤ 2 x ULN (except patients with documented Gilbert's syndrome) 6.f Creatinine < 2 mg/dl (or a glomerular filtration rate > 60)
- •Prior palliative radiotherapy must have been completed at least 2 weeks prior to start the study treatment (subjects may receive localized palliative radiotherapy while receiving study drug).
- •Subjects with brain metastases are eligible if they are asymptomatic, are treated or are neurological stable for at least 2 weeks without the use of steroids or on stable or decreasing dose of < 10 mg daily prednisone or equivalent.
- •Must be willing and able to accept one leukapheresis procedures
排除标准
- •Prior chemotherapy for extensive-stage ES-SCLC
- •Any syndrome that requires systemic corticosteroid/immunosuppressive medication EXCEPT for syndromes which would not be expected to recur in the absence of an external trigger (vitiligo, autoimmune thyroiditis, or type 1 diabetes mellitus are permitted to enroll)
- •Active or prior documented inflammatory bowel disease (e.g., Crohn’s disease, ulcerative colitis).
- •History of primary immunodeficiency.
- •History of allogeneic organ transplant.
- •History of hypersensitivity to atezolizumab / ADC immunotherapy or any excipient.
- •Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, active peptic ulcer disease or gastritis, active bleeding diathesis including any subject known to have evidence of acute or chronic hepatitis B or C, or psychiatric illness/social situations that would limit compliance with study requirements or compromise the ability of the subject to give written informed consent.
- •Known history of active tuberculosis.
- •Subjects with previous malignancies (except for non melanoma skin cancer, and cancer in situ of: bladder, gastric, colon, cervical/dysplasia, melanoma, breast) are excluded unless a complete remission was achieved at least 5 years prior to study entry and no additional therapy is required or anticipated to be required during the study period.
- •Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving atezolizumab. Note: For COVID vaccination, every case should be first consulted with the Clinical Trial Coordinator. Decisions to administer vaccine should be individualized by the physicians and in consultation with the patients and based on the risk of SARS-CoV-2 infection/complications and potential benefit from the vaccine, the general condition of the patient, underlying disease, and the severity of COVID-19 outbreak in a given area/ region.
- •Prior allogeneic stem-cell transplantation.
- •Any prior anti PD-1/PD-L1 antibody therapy
- •Known severe hypersensitivity reactions to monoclonal antibodies (Grade ≥ 3 NCI-CTCAE v 5.0), any history of anaphylaxis, or uncontrolled asthma.
- •Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ highly effective birth control from screening to 180 days after the last dose of ADC + atezolizumab combination therapy.
- •History of, or significant evidence of risk for, severe chronic inflammatory or autoimmune disease
- •Potential requirement for systemic corticosteroids or concurrent immunosuppressive drugs based on prior history or received systemic steroids within the last 2 weeks prior to enrollment (inhaled or topical steroids at standard doses are allowed)
- •Human immunodeficiency virus (HIV) seropositivity, active Hepatitis B or C seropositivity (also exclusion of Ags negative with anti Core positive)
- •Dementia or significantly altered mental status that would prohibit the understanding or rendering of informed consent and compliance with the requirements of this protocol
- •Pregnancy or breastfeeding; female patients must be surgically sterile or be postmenopausal for two years, or must agree to use effective contraception during the period of treatment and 6 months after; all female patients with reproductive potential must have a negative pregnancy test (serum/urine) within 24 hours from starting the conditioning chemotherapy; the definition of effective contraception will be based on the judgment of the study investigators; patients who are breastfeeding are not allowed on study
- •Any unresolved toxicity (CTCAE grade 2) from previous anti-cancer therapy. Subjects with irreversible toxicity that is not reasonably expected to be exacerbated by the investigational product may be included (e.g., hearing loss, peripheral neuropathy).
- •Active or prior documented autoimmune disease within the past 2 years NOTE: Subjects with vitiligo, Grave’s disease, or psoriasis not requiring systemic treatment (within the past 2 years) are not excluded. For the phase I cohort, patients with autoimmune paraneoplastic syndromes will be also excluded.
结局指标
主要结局
Progression-Free Survival (PFS) rate at 6 months: Calculated as the percentage of participants alive and without disease progression, as assessed by the Investigator using RECIST v1.1, at 6 months.
Progression-Free Survival (PFS) rate at 6 months: Calculated as the percentage of participants alive and without disease progression, as assessed by the Investigator using RECIST v1.1, at 6 months.
次要结局
- Duration of clinical benefit (DCB) as per RECIST 1.1: DCB calculated as the time (in months) from first dose of treatment to progression (or death from any cause) in patients who had a best overall response of CR, PR, or SD of ≥ 24 weeks.
- Response rate (ORR): rate of patients that achieve partial or complete response as best response during study induction treatment (ORR1) and rate of patients that have a further best response during maintenance treatment (ORR2).
- Overall Survival (OS): Overall Survival (OS) is calculated as the time from date of inclusion to date of death due to any cause.
研究者
A person designed by the Sponsor
Scientific
Instituto Oncologico Dr. Rosell S.L.
研究点 (3)
Loading locations...
相似试验
招募中
3 期
A Study Evaluating the Efficacy and Safety of Neoadjuvant Treatment with Atezolizumab or Placebo in Combination with Platinum-Based Chemotherapy in Patients with Resectable Stage II, IIIA, or Select IIIB Non-small cell lung cancer2023-504209-35-00F. Hoffmann-La Roche AG207
已完成
3 期
A Comparative Study of atezolizumab(MPDL3280A)With standard chemotherapy in Patients With Stage IV NSCLCon-Small Cell Lung CancerJPRN-jRCT2080222849Chugai Pharmaceutical Co., Ltd.572
尚未招募
2 期
SPARTANA : Spartalizumab, mDCF (docetaxel, cisplatin and 5-fluorouracil) and radiotherapy in patients with metastatic squamous cell anal carcinoma.2024-516005-23-00Centre Hospitalier Regional Universitaire34
已完成
3 期
A Phase III Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-paclitaxel Compared With Carboplatin + Nab-paclitaxel in Patients With Stage IV Squamous NSCLCon-Small Cell Lung CancerJPRN-jRCT2080222847Chugai Pharmaceutical Co., Ltd.1,021
已完成
2 期
A first-in-human clinical trial in adult patients with advanced non-small cell lung cancer of a personalised therapy targeting specific mutations that occur in all cancer cells within a single patientNon-small cell lung cancer2024-513060-26-00Achilles Therapeutics UK Limited24